Skip to main content

Repurposing a known drug to treat heart diseases

Project description

A multiple sclerosis drug for heart failure

Coronary heart disease is the leading cause of death in developed countries with millions of cases in Europe alone. It is associated with decreased blood flow to the heart, which may lead to heart attacks. To address cardiac muscle repair, which is the key problem after a heart attack, the EU-funded ReDHeaD project will test the FDA-approved drug copaxone, which is used in the treatment of multiple sclerosis. Preclinical data demonstrate significant improvement in heart function parameters following copaxone administration. Researchers will prepare for clinical trials to validate the efficacy of the drug in humans and undertake all the necessary regulatory and commercialisation activities for its rapid clinical translation.

Host institution

WEIZMANN INSTITUTE OF SCIENCE
Net EU contribution
€ 150 000,00
Address
Herzl Street 234
7610001 Rehovot
Israel

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
No data

Beneficiaries (1)

WEIZMANN INSTITUTE OF SCIENCE
Israel
Net EU contribution
€ 150 000,00
Address
Herzl Street 234
7610001 Rehovot

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
No data